Alphamab and 3DMed Join Hands in Developing New Anti-tumor Drug
On the morning of February 29, Alphamab Co. Ltd signed a cooperation agreement with 3DMed on the joint development of KN035 biological reagent of the new generation PD-L1 single domain anti-body.
It is reported that the new drug, PD-L1 single domain anti-body, to be developed by the two sides, will focus on the immunity against tumors.
"The new anti-tumor drug will be applied for hypodermic injection instead of the current traditional intravenous injection, and is therefore more safe and acceptable to the patient," said Gong Zhaolong, CEO of 3DMed. As a stable reagent, the anti-body of new type will reinforce the attack on tumors by the immunity cells of the human body with little toxic side effect. Application report is expected to be filed in the near future both in China and the US for clinical trial of the new drug. The cooperation between Alphamab and 3DMed will be completely on equal footing in matters of applying for clinical experiment, clinical study, market sales, and production.
March 1, 2016